Kornimate/medical-research-clean huggingface dataset:
long-term effect of hypnosis in spinal cord injury patients

Conditions: Spinal Cord Injuries

Summary: coping-oriented hypnotic suggestions aimed at reducing pain catastrophizing was shown to reduce pain in people with chronic tension-type headache and experimental pain in healthy volunteers during hypnosis (kjøgx et al., 2016). however, the duration of the effect on pain post-hypnosis is unknown. the aim is to investigate the durational effect of a single session of coping-oriented hypnotic suggestions on chronic pain in patients with spinal cord injury. if effective for a longer period post-hypnosis, this form of hypnosis may provide an alternative to medicine or may be used in conjunction with lower medicine dosages. methods: 75 patients with spinal cord injury and pain is randomized into one of three conditions; coping-oriented hypnosis plus current treatment, neutral hypnosis plus current treatment or current treatment only. pain intensity, coping strategies, pain catastrophizing, anxiety and depression is assessed before intervention and over a period of 14 days post-intervention.


Eligibility criteria:
inclusion criteria: * spinal cord injury (tetraplegia or paraplegia) with some preservation of hand functioning * baseline pain level of ≥ 3 on a numeric rating scale (nrs; 0-10 where 10 is extremely severe pain) * pain duration of at least 8 weeks. exclusion criteria: * severe mental or psychiatric illness * substance abuse (drugs, alcohol or medicine) * lack of ability to cooperate during the experiment * severe high cervical lesions * severe autonomic dysautonomia

Keywords: spinal cord injury hypnosis pain pain catastrophizing coping
robotic assisted sacral colpopexy : a prospective study assessing outcomes with learning curves

Conditions: Pelvic Organ Prolapse

Summary: the investigators scientific aims are to determine the benefits associated with the use of robotic assisted laparoscopic sacrocolpopexy surgery on women with prolapse, to define how the benefits impact the patient, physician and the institution, and to determine the complications associated with the use of the robot. this will be a prospective cohort following 100 patients for a 24 month period.

the investigators scientific aims are to determine the benefits associated with the use of robotic assisted laparoscopic sacrocolpopexy surgery on women with prolapse, to define how the benefits impact the patient, physician and the institution, and to determine the complications associated with the use of the robot. this will be a prospective cohort following 100 patients for a 24 month period. the investigators primary outcomes will be: * surgical time: key portion of procedure will be assessed along with total time for completion * learning curve: will be assessed using surgical times, vas of camera skills, surgical skills involving tissue handling and movements and overall performance by surgeon, assistant and blind reviewer * length of hospitalization: measured by days in hopsital the investigators secondary outcomes will be: * pre-operative and postoperative pelvic organ prolapse-quantification (pop-q) at 6 week, 6, 12, and 24 months. * pelvic floor distress inventory-short form 20 questionnaire (pfdi-20) * mesh erosion, * estimated blood loss, * complications (bowel or bladder injury) and, * wound infection, * patient global impressions of improvement * pelvic organ prolapse/urinary incontinence sexual questionnaire (pisq-12).

Eligibility criteria:
inclusion criteria: * \> 18 years old * females only * undergoing robotic assisted laparoscopic sacrocolpopexy with or without other procedures for pelvic organ prolapse * willing to return for follow-up visits * written informed consent obtained from each subject exclusion criteria: * decline to participate * pregnant or contemplating future pregnancy (within a year) * unable to participate in the informed consent process

Keywords: robotic sacral colpopexy learning curve pelvic organ prolapse robotic surgery
an intervention study to improve therapeutic compliance in adult patients with eosinophilic esophagitis.

Conditions: Eosinophilic Esophagitis

Summary: in many chronic conditions adherence to long-term treatment is a challenge, also for patients with eosinophilic esophagitis. interventions, such as behavioral, educational and reminder interventions might improve treatment adherence. with this trial the investigators want to assess the effects of additional education in combination with more frequent follow up and patient reminders on adherence to treatment in adult patients with eosinophilic esophagitis.


Eligibility criteria:
inclusion criteria: * written informed consent * male or female patient * age \>18 years * previous diagnosis of eoe, confirmed by histopathology, with the presence of \>15 eosinophilic granulocytes per high power field (hpf) in esophageal biopsies * current maintenance treatment for eoe with a ppi or swallowed topical corticosteroids or about to start with these maintenance medications as decided during regular clinical practice exclusion criteria: * severe and clinically unstable concomitant disease that may interfere with the subject's ability to participate in the study * receive investigational treatment during the study * dilation of esophagus required * insufficient dutch or english language skills to understand patient information leaflets

Keywords: eosinophilic esophagitis maintenance treatment compliance intervention
intraoperative nociception and postoperative pain

Conditions: Pain, Postoperative; Nociceptive Pain; Analgesics

Summary: if the individual patient's pain is assessed and the amount of analgesic needed after surgery is predicted, appropriate injection of pain control and excessive injection of narcotic analgesic can be prevented. therefore, investigators try to evaluate the relation intraoperative nociception response with postoperative pain score. in similar anesthetic depth(end tidal sevoflurane 3%) , changes of surgical pleth index values for stimulus of skin incision are thought to reflect the individual nociception characteristics.

patients who undergoing upper abdominal laparotomy surgery usually experience severe postoperative pain. previous studies were reported that preoperative pain, young age, high-dose remifentanil, and depression were associated with severe postoperative pain. however, anesthesia-related studies were either retrospective studies or injected with anesthetic agents in excess of clinical doses to differentiate between groups. there is no objective indicator for prediction severe postoperative pain.the purpose of this study was to investigate the relationship between intraoperative pain response and postoperative pain on standardized surveillance devices. to maintain the depth of anesthesia, an eeg monitoring device bispectral index (bis) is used. also, surgical pleth index (spi, ge healthcare, freiburg, germany) is a noninvasive pain-analgesia balance monitoring device that is commercially available to evaluate the state of pain during general anesthesia. spi = 100- (0.3 \* heart beat interval + 0.7 \* photoplethysmographic pulse wave amplitude) is automatically and continuously calculated from the waveform of peripheral oxygen saturation. in similar anesthetic depth(end tidal sevoflurane 3%) , changes of spi values for stimulus of skin incision are thought to reflect the individual nociception characteristics. the investigators hypothesized the higher analgesics consumption can predict with high spi response following incisional stimuli. thus, investigators try to evaluate the comparison of two groups ( high fentanyl consumption group vs. low fentanyl consumption group) with intraoperative spi value (incision and before aurosal) and hemodynamic parameters under end tidal sevoflurane 3%(anesthesia depth, hemodynamically stable and appropriate anesthetic depth based on previous studies were confirmed at the time of skin incision). and the characteristics and emotional status of patients in two groups are compared.

Eligibility criteria:
inclusion criteria: -undergoing laparotomy gastrectomy exclusion criteria: * cardiac arrythmia * allergic history for drugs * renal failure (cr\> 1.5 mg/dl)
low dose morphine to relieve dyspnea in acute respiratory failure (opidys)

Conditions: Acute Respiratory Failure

Summary: this study evaluates a pharmacological intervention to relieve dyspnea in intensive care unit patients. indeed, opioids can be particularly beneficial since 1) dyspnea and pain share many similarities, 2) the benefit of opioids on dyspnea has been clearly demonstrated in other populations. however, to date, data regarding the impact of morphine on dyspnea in intensive care unit patients admitted for acute respiratory failure are scarce. there may be a reluctance of physicians to prescribe opioids that is not scientifically justified. the study will focus on patient reported outcome (pro) criteria. the ultimate goal of this pilot study is to design the protocol of a future pragmatic trial.

randomized, double-blind, placebo-controlled, parallel-group, single-center phase 2 pilot study.the experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol. the control group will receive placebo nacl 0.9% administered according to the same protocol as the experimental arm patients will be randomized 1:1 between low-dose titrated morphine (experimental group) and placebo (control group). the other treatments will be similar in both groups, according to the protocol and the recommendations. severe dyspnea will be assessed for regularly patients will be followed for 48 hours: 24-hour treatment duration, evaluation of primary endpoint for first 24 hours, collection of adverse events for 48 hours.

Eligibility criteria:
inclusion criteria: * adult patients ≤ 75 years * admitted in intensive care for an acute respiratory failure defined as a respiratory rate\> 24 / min or signs of respiratory distress such as labored breathing or paradoxical inspiration, or spo2 \<90% in ambient air * spontaneous ventilation, either under standard oxygen, high flow oxygen or non invasive ventilation * dyspnea ≥ 40 on an dyspnea-vas from zero (no dyspnea) to 100 (worst possible dyspnea) * richmond agitation and sedation scale (rass) between 0 and 2. * no confusion, as defined by the cam-icu * signed informed consent exclusion criteria: * intubated patient * intubation planned upon admission * hearing or visual impairment * insufficient command of french * previous psychiatric or cognitive disorders known * moribund patient * known hypersensitivity to opioids * severe renal insufficiency (creatinine clearance \<30 ml / min) * severe hepatocellular insufficiency (factor v \<50%) * any formal contra-indication of opiates * opioid use within the 24 hours before inclusion * pregnancy or breastfeeding * minor and protected adult * exclusion period due to inclusion in another clinical trial * previous inclusion in this study * no affiliation to social security

Keywords: acute respiratory failure dyspnea opioids comfort intensive care unit
validation study of mhealth technology in hiv to improve empowerment and healthcare utilisation: research and innovation to generate evidence for personalised care (emerge)

Conditions: HIV Infections

Summary: a large (3900 patients) cohort study, undertaken in five european sites to validate in a mhealth platform to enable self-management of hiv in patients with stable disease using a tailored hta process, model for assessment of telemedicine applications (mast), specifically developed for the assessment of mhealth solutions. as site recruitment will be sequential and the recruitment period will last 18 months, a maximum follow-up of 35 months will be undertaken. study visits will take place at baseline defined as the time of mhealth introduction, months 6, 12, 18, 24 and 30.

number of study centres: 5 duration of study: 35 months criteria for evaluation: usability of the mhealth platform, patient self-management and empowerment, clinical safety (virological suppression maintenance, cd4 count, laboratory parameters, adverse events and adherence), quality of life and self-economy will be assessed by questionnaires and laboratory parameters. routine data on patient demographics, treatment and investigations which will include viral load, cd4, haematology, biochemistry and urine sample. patient activation measure, quality of life, adherence questionnaire and economic questionnaires will be performed at baseline and at months 12 and 24. satisfaction system usability scale will be evaluated at month 12 and 24.

Eligibility criteria:
inclusion criteria: 1. documented hiv-1 infection 2. aged at least 18 years old 3. able to give informed consent 4. in possession of a smartphone, tablet, or similar technology supporting the mhealth platform 5. stable on art: defined as art should be unchanged for at least 3 months and viral load undetectable (\<50 copies/ml) for at least 6 months. 6. clinically stable from an hiv perspective: defined as without opportunistic infection or aids related cancers within the previous 12 months exclusion criteria: 1. aged less than 18 years 2. pregnant 3. participating in a clinical trial or receiving an investigational medication 4. unable to comprehend the patient information sheet 5. unable to comprehend the instructions for using the mhealth platform 6. considered for any other reason by their regular physician to be unsuitable for study participation.
split scripts for pediatric supracondylar fracture repairs

Conditions: Pain, Postoperative

Summary: this study is designed to test the hypothesis that increased electronic order-set compliance and focused education will decrease the amount of unconsumed opioid entering and remaining in the home after pediatric supracondylar fracture repair the proposed study will address the hypothesis with the following objectives: 1. investigators will increase compliance with previously implemented standardized precision-based electronic discharge order sets; 2. investigators will introduce part-fill opioid prescriptions for supracondylar fracture repairs; 3. investigators will increase parental compliance with home administration of simple (non-opioid) analgesics; 4. investigators will decrease opioid amount remaining in the home pre and post 3-week follow up.

canada has one of the highest opioid prescribing rates in the world (united nations, 2018). in 2017, health quality ontario published a major report that identified the number of opioid prescriptions following surgery were second only to those following dentist office visits. as a result, health quality ontario made the reduction of opioid prescribing ('cut the count)' their number one provincial healthcare priority of 2019. to date, investigators have decreased mme amount of opioid entering the home post-supracondylar fracture repair at approximately 10 mme per patient and increased the rate of return of unused drug by 10 mme per patient. the hospital for sick children alone performs some 200 such surgeries per year, representing 4,000 mg of morphine (four grams) that the community is no longer exposed to. this is only one surgery type in one hospital; expansion of our methodology to other surgeries (currently expanding to dental and cleft palates) and other institutions will dramatically decrease unintentional but iatrogenic home exposure of children and families to unwarranted and dangerous drugs. this latest study aims to address all three steps outlined in the 2020-2021 health quality ontario surgical mandate for children discharged from the hospital for sick children after supracondylar fracture repair.

Eligibility criteria:
inclusion criteria: * patients with type ii or type iii supracondylar fractures undergoing surgical wire placement or pinning that return to fracture clinic at three weeks for removal of pins/wires. exclusion criteria: * patients who are not prescribed morphine following a supracondylar fracture repair surgery
colchicine to reduce your symptoms and lower levels of inflammation, zeroing in on effective cppd disease treatment

Conditions: CPPD - Calcium Pyrophosphate Deposition Disease

Summary: the goal of this clinical trial is to learn if colchicine reduces levels of proteins indicating inflammation in the blood in individuals with calcium pyrophosphate deposition (cppd) disease. the trial will also test the effect of colchicine on joint symptoms in cppd disease. the main questions it aims to answer are: * does colchicine reduce the level of interleukin 18 (il-18) in the blood of individuals with cppd disease? * does colchicine reduce pain scores in individuals with cppd disease? researchers will compare colchicine once daily to a placebo (a look-alike pill that contains no drug) to see if colchicine works to treat cppd disease. participants will: * take colchicine or a placebo every day for 6 months * visit the clinic 3 times in 6 months for joint examinations, surveys, and blood tests. each visit will last 2-3 hours. * speak on the telephone with researchers for about 4 times over 6 months. each phone call will last about 5 minutes.


Eligibility criteria:
inclusion criteria: * provide written informed consent * fulfill acr/eular 2023 cppd classification criteria * acute or chronic joint inflammation in the past 3 months, not attributable to another condition * pain visual analog scale (pain vas) \>=30 at screening exclusion criteria: * age \<40 years * chronic diarrhea * gout, rheumatoid arthritis, or psoriatic arthritis * cirrhosis * ongoing use of colchicine and unwilling to undergo a 30-day wash-out period (note: patients using colchicine at screening can enroll if they agree to a 30-day wash-out before randomization) * pregnant or breast-feeding * use of methotrexate, hydroxychloroquine, or anakinra in the past month * use of oral glucocorticoid in the past week * use of strong cyp3a4 inhibitors per fda package insert for colchicine * use of p-glycoprotein inhibitors per fda package insert for colchicine * known allergy to colchicine screening labs with any of the following: * hemoglobin \< 11.5 g/dl * wbc \<3 x 10\^9/l * platelets \<110 x10\^9/l * creatinine clearance (crcl) \<30 ml/min * alt or ast \>3x upper limit of normal (uln)

Keywords: colchicine cppd disease calcium pyrophosphate pseudogout
folate-rich foods improve folate status

Conditions: Folic Acid Deficiency

Summary: this study evaluates the effects of folate-rich foods regarding improvement of folate status compared with folic acid supplement. a randomized, parallel intervention trial with two active groups (folate-rich foods or folic acid supplement) and one control group (apple juice - 0 µg/d folate) was executed over 12 weeks.

sixty-two women in reproductive age, apparently healthy, non-smokers, not consuming special diets (vegetarian), not pregnant, not planning conception or not lactating. a randomized, controlled, parallel intervention trial with two active groups and one blinded control group was carried out for 12 weeks (march to june, 2013). the active food group (n = 21) consumed folate-rich foods (germinated canned faba beans, cookies, orange juice, providing additional 250 μg/d folate); the active folic acid supplement group consumed a supplement (n = 19, providing 500 μg/d folic acid); and the control group (n = 22) received apple juice containing no folate or folic acid) in addition to the freely chosen diet. fasted venous blood samples were collected at baseline, two months and three months for quantification of folate in plasma and erythrocytes and of homocysteine in plasma.

Eligibility criteria:
inclusion criteria: normal biochemical range for: * fasted plasma glucose * iron status (haemoglobin, serum ferritin) * liver status (aspartate transaminase, alanine transaminase, and γ-glutamyl transferase activities) * lipid profile (triglycerides, ldl, hdl) * folate status (plasma and erythrocyte folate) * plasma total homocysteine (thcy) * vitamin b-12 exclusion criteria: * history of acute or chronic disease * use of vitamin or mineral supplements or folic acid fortified foods (within the past one month) * a body mass index (bmi, in kg/m2) \>18 and \<30 * any medication interfering with folate metabolism (e.g., antiepileptic drugs, antibiotics, methotrexate, sulfasalazine, or anticonvulsants), smokers, consuming special diets (vegetarian), pregnancy, planned conception or lactation

Keywords: folate folic acid intervention trial folate status women in childbearing age food folate
epigenetic regulation of osteogenesis imperfecta severity : miroi study

Conditions: Osteogenesis Imperfecta

Summary: osteogenesis imperfecta (oi) is a heterogeneous group of rare connective tissue hereditary diseases responsible for fragility and bone deformity. oi is caused by an autosomal dominant mutation of col1a1 or col1a2, encoding α1 and α2 of the collagen, regardless of their phenotypic severity (1 to 5 oi type). this observation suggests the existence of a undetermined mechanism that may be found in epigenetic regulation, including particularly micro ribonucleic acids (mirs). indeed, these small non-coding mirs are involved in the regulation of major steps of cellular processes in different pathologies, especially in bone disease. currently, no study can provide a satisfactory answer. this is an etiologic study to reveal the correlation between micro-rnas (mir) expression and the type i or iii of the osteogenesis imperfecta (oi). the aim of this study is therefore to identify mirs significantly associated with the severity of oi.


Eligibility criteria:
inclusion criteria: control population: * male or female * 18 years old and over * be part of cohorts strambo, ofely or modam patients with oi: * male or female ≥18 years old * have col1a1 or col1a2 mutation * have a diagnosis of type 1 or 3 from silence classification made by a rheumatologist expert in bone pathologies exclusion criteria: * refusal to participate in the study * have received glucocorticoid treatment for more than 3 months * have received anti-osteoporotic treatment for less than 1 year ago * have chronic inflammatory rheumatism * have an uncontrolled hypo/hyper thyroidism ou hypo/hyper parathyroidism * have cancer or bone metastases (current or in the past two years) * have benign bone tumors or paget's disease * have malabsorptive disease (celiac disease, whipple's disease, intestinal bypass, short bowel syndrome) and inflammatory bowel disease * pregnant or lactating women * have psychiatric disorders seriously hindering understanding * have difficulties in oral understanding of french language * not a beneficiary of french social security * patients protected by law

Keywords: osteogenesis imperfecta micro ribonucleic acids epigenetics
effects of hypnosis therapy on outcomes in shoulder replacement therapy

Conditions: Anxiety; Opioid Use

Summary: the purpose of this study is to collect information to evaluate the role of the psychogenic component of pain induced by anxiety on postoperative outcomes in major orthopaedic surgery and to determine whether hypnosis therapy provided during the perioperative period will lead to decreased use of opioid therapy. patients are randomly assigned to one of two treatment groups: (i) usual care, or; (ii) hypnotherapy treatment. patients have an equal chance of being assigned to one of the two groups.


Eligibility criteria:
inclusion criteria: * diagnosis of primary shoulder osteoarthritis, massive cuff tear arthropathy, and rotator cuff arthropathy requiring a primary total or reverse shoulder replacement, * the ability to read, speak, and understand english * the ability and willingness to use a web-based application (oberd) on a smartphone, pad, or computer, and * 18 years of age or older. exclusion criteria: * shoulder replacement for the treatment of acute proximal humerus fractures * hemiarthroplasty * revision shoulder replacement * patients with active cancer or receiving palliative care * less than 18 years of age

Keywords: hypnosis shoulder arthroplasty